|
業務類別
|
Biotechnology |
|
業務概覽
|
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies. |
| 公司地址
| 770 Lindaro Street, San Rafael, CA, USA, 94901 |
| 電話號碼
| +1 415 506-6700 |
| 傳真號碼
| +1 415 382-7889 |
| 公司網頁
| https://www.biomarin.com |
| 員工數量
| 3221 |
| Mr. G. Eric Davis |
Executive Vice President, Chief Legal Officer and Secretary |
-- |
21/04/2026 |
| Mr. Brian R. Mueller |
Executive Vice President and Chief Financial Officer |
美元 721.15K |
21/04/2026 |
| Dr. Charles Greg Guyer, PhD |
Chief Technical Officer and Executive Vice President |
美元 697.12K |
21/04/2026 |
| Mr. Alexander Hardy |
Director, President and Chief Executive Officer |
美元 1.13M |
21/04/2026 |
| Ms. Cristin Hubbard |
Executive Vice President and Chief Commercial Officer |
美元 662.31K |
21/04/2026 |
| Dr. Gregory R. Friberg, M.D. |
Executive Vice President and Chief Research and Development Officer |
美元 705.65K |
21/04/2026 |
| Ms. Rashmi Virendra Ramchandani |
Vice President and Chief Accounting Officer |
-- |
21/04/2026 |
|
|
| Mr. Ian T. Clark |
Chairman of the Board |
04/06/2026 |
| Mr. Timothy P. Walbert |
Independent Director |
21/04/2026 |
| Dr. Willard H. Dere, M.D. |
Independent Director |
21/04/2026 |
| Mr. Robert J. Hombach |
Independent Director |
21/04/2026 |
| Dr. Athena Countouriotis, M.D. |
Independent Director |
21/04/2026 |
| Mr. Mark Joseph Enyedy |
Independent Director |
21/04/2026 |
| Dr. Maykin Ho, PhD |
Independent Director |
21/04/2026 |
| Ms. Barbara W. Bodem |
Independent Director |
21/04/2026 |
| Ms. Elizabeth McKee Anderson, M.B.A. |
Independent Director |
21/04/2026 |
| Mr. Alexander Hardy |
Director, President and Chief Executive Officer |
21/04/2026 |
|
|
|
|
